Shares in Wegovy maker Novo Nordisk fell around 4% on Friday to their lowest since August 2021, after U.S. President Donald ...

Furious competition in GLP-1 drugs rebuts the anti-pharma crowd.

Some health experts view GLP-1s as a promising option for PCOS, which lacks a standard treatment and affects millions of ...

Hims & Hers Health partnered with Novo Nordisk earlier this year, only for that to unravel shortly afterward due to controversial practices around the sale of compounded drugs.

Novo Nordisk A/S (NYSE:NVO) is one of the 10 Best Growth Stocks to Buy With Huge Upside Potential. On June 23, Novo Nordisk A/S (NYSE:NVO) announced that the European Medicines Agency’s ...

Novo Nordisk's beaten-down valuation became too attractive to pass up, so I bought the stock earlier this year. Eli Lilly's GLP-1 drugs may have more potential, but Novo Nordisk is still likely to ...

Today's Must Read SAP Revenue Growth Fueled by Strong Cloud Momentum GLP-1 Drugs Boost Novo Nordisk (NVO), Market Rivalry a Woe End Market Strength, Innovations Aid Thermo Fisher (TMO) Featured ...

Novo Nordisk will lose its patent protection on its branded semaglutide drugs Ozempic and Wegovy in Canada after not paying a maintenance fee in 2019.

Novo Nordisk A/S (NYSE: NVO) is one of the 10 best defensive stocks to buy in a volatile market. On July 7, the company received a significant boost in its proposed $2.34 billion investment in a ...